Cited by 154SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesAnimal Virus Infections Studies

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct

Open access

Mykytyn, Anna Z., Rissmann, Melanie, Kok, Adinda, Rosu, Miruna E., Schipper, Debby, Breugem, Tim I., van den Doel, Petra B., Chandler, Felicity, Bestebroer, Theo, de Wit, Maurice, van Royen, Martin E., Molenkamp, Richard, Oude Munnink, Bas B., de Vries, Rory D., GeurtsvanKessel, Corine, Smith, Derek J., Koopmans, Marion P. G., Rockx, Barry, Lamers, Mart M., Fouchier, Ron A. M., Haagmans, Bart L.·2022·Science Immunology

DOI 10.1126/sciimmunol.abq4450PMC PMC9273038

Open this paper in CoChat — free account

Abstract

The emergence and rapid spread of SARS-CoV-2 variants may affect vaccine efficacy substantially. The Omicron variant termed BA.2, which differs substantially from BA.1 based on genetic sequence, is currently replacing BA.1 in several countries, but its antigenic characteristics have not yet been assessed. Here, we used antigenic cartography to quantify and visualize antigenic differences between early SARS-CoV-2 variants (614G, Alpha, Beta, Gamma, Zeta, Delta, and Mu) using hamster antisera obtained after primary infection. We first verified that the choice of the cell line for the neutralization assay did not affect the topology of the map substantially. Antigenic maps generated using pseudo-typed SARS-CoV-2 on the widely used VeroE6 cell line and the human airway cell line Calu-3 generated similar maps. Maps made using authentic SARS-CoV-2 on Calu-3 cells also closely resembled those generated with pseudo-typed viruses. The antigenic maps revealed a central cluster of SARS-CoV-2 variants, which grouped on the basis of mutual spike mutations. Whereas these early variants are antigenically similar, clustering relatively close to each other in antigenic space, Omicron BA.1 and BA.2 have evolved as two distinct antigenic outliers. Our data show that BA.1 and BA.2 both escape vaccine-induced antibody responses as a result of different antigenic characteristics. Thus, antigenic cartography could be used to assess antigenic properties of future SARS-CoV-2 variants of concern that emerge and to decide on the composition of novel spike-based (booster) vaccines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/sciimmunol.abq4450

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1. Neutralizing activity of human post-vaccination sera against Omicron BA.1 and BA.2. (A-C) Neutralization titers against 614G, Delta, Omicron BA.1 and Omicron BA.2 of vaccinated individuals after vaccination with one (A), two (B) or three (C) doses of BNT162b2. Geometric mean is displayed above each graph. PRNT50: plaque reduction neutralization titers resulting in 50% plaque reduction. Dotted lines indicate limit of detection. One way ANOVA was performed for statistical analysis. *p<0.05. N=10.CC BY · PubMed Central

Fig. 2. SARS-CoV-2 variants efficiently infect hamsters, inducing high neutralizing antibody titers. (A) Hamsters were inoculated with the indicated SARS-CoV-2 variants. Nasal washes were collected 7 days post-infection and sequenced. At 26 days post-infection blood was collected for serological analysis. (B) Hamster antisera were assessed for neutralizing antibodies against pseudotyped and authentic SARS-CoV-2. PRNT50 values were used to generate antigenic maps using a multidimensional scaling algorithm. (C) RNA titers of nasal washes collected one day post-infection. (D) Homologous PRNT50 titers were determined using authentic SARS-CoV-2. Geometric mean is displayed above graph. PRNT50: plaque reduction neutralization titers resulting in 50% plaque reduction. Dotted line indicates limit of detection. Error bars indicate SEM. Panels A and B were created with BioRender.com.CC BY · PubMed Central

Fig. 3. Antigenic maps comparing neutralizations with SARS-CoV-2 pseudoviruses and authentic SARS-CoV-2. (A-B) MDS was used to create an antigenic map from the PRNT50 titers generated against 614D, 614G, Alpha, Beta, Delta, Kappa and Omicron pseudoviruses on either VeroE6 (A) or Calu-3 (B) cells. (C) MDS was used to create an antigenic map from the PRNT50 titers generated against 614G, Alpha, Beta, Delta and Omicron authentic SARS-CoV-2. (D) Re-display of antigenic map in C with lilac arrows indicating antigen positions in map A and black arrows indicating antigen positions in map B. Viruses are shown as colored circles and antisera as squares with the same outline color as the matching viruses. Viruses and antisera are positioned in the map so that the distances between them are inversely related to the antibody titers, with minimized error. The grid in the background scales to a 2-fold dilution of antisera in the titrations. MDS: multidimensional scaling. PRNT50: plaque reduction neutralization titers resulting in 50% plaque reduction.CC BY · PubMed Central

Fig. 4. Antigenic cartography using authentic SARS-CoV-2. (A-H) Neutralizing titers of hamsters infected with either (A) 614G, (B) Alpha, (C) Beta, (D) Gamma, (E) Zeta, (F) Delta, (G) Mu or (H) Omicron BA.1 viruses. (I) Multidimensional scaling was used to create an antigenic map utilizing PRNT50 titers generated from authentic SARS-CoV-2 on Calu-3 cells. See legend to Fig. 3 for details. Subdivided by dotted ellipses are variants possessing overlapping substitutions as indicated. Geometric mean is displayed above each graph. PRNT50: plaque reduction neutralization titers resulting in 50% plaque reduction. Dotted lines indicate limits of detection. Error bars indicate SEM.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Self-citation
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
Mapping the Antigenic and Genetic Evolution of Influenza Virus
Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2004) · Science · doi:10.1126/science.1097211 · Cited by 1,868
Self-citation
SARS-CoV-2 productively infects human gut enterocytes
Lamers, M. M., Beumer, J., van der Vaart, J., Knoops, K., Puschhof, J., Breugem, T. I., Ravelli, R. B. G., Paul van Schayck, J., Mykytyn, A. Z., Duimel, H. Q., et al. (2020) · Science · doi:10.1126/science.abc1669 · Cited by 1,573
Self-citation
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03944-y · Cited by 1,337
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Pathogenesis and transmission of SARS-CoV-2 in golden hamsters
Sia, S. F., Yan, L.-M., Chin, A. W. H., Fung, K., Choy, K.-T., Wong, A. Y. L., Kaewpreedee, P., Perera, R. A. P. M., Poon, L. L. M., Nicholls, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2342-5 · Cited by 1,303

Show all 35 references

Research works printed but not linked: 1

10.1038/s41586-021-04387-1 · DOI · Paper page

Sorted by citations

Mapping SARS-CoV-2 antigenic relationships and serological responses
Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134
Self-citation
Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity
Aguilar-Bretones, M., Fouchier, R. A. M., Koopmans, M., & van Nierop, G. P. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162192 · Cited by 108
Self-citation
Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron
van der Straten, K., Guerra, D., van Gils, M. J., Bontjer, I., Caniels, T. G., van Willigen, H. D. G., Wynberg, E., Poniman, M., Burger, J. A., Bouhuijs, J. H., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.018 · Cited by 125
Population immunity predicts evolutionary trajectories of SARS-CoV-2
Meijers, M., Ruchnewitz, D., Eberhardt, J., Łuksza, M., & Lässig, M. (2023) · Cell · doi:10.1016/j.cell.2023.09.022 · Cited by 102
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Rössler, A., Netzl, A., Knabl, L., Schäfer, H., Wilks, S., Bante, D., Falkensammer, B., Borena, W., von Laer, D., Smith, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35312-3 · Cited by 78
Self-citation
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
van Leeuwen, L. P. M., GeurtsvanKessel, C. H., Ellerbroek, P. M., de Bree, G. J., Potjewijd, J., Rutgers, A., Jolink, H., van de Veerdonk, F. L., Gorp, E. C. M. V., de Wilt, F., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.04.002 · Cited by 67
Self-citation
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history
Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R. A., Coggins, S. A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.012 · Cited by 59
Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection
Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68
Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
Mykytyn, A. Z., Rosu, M. E., Kok, A., Rissmann, M., van Amerongen, G., GeurtsvanKessel, C. H., de Vries, R. D., Munnink, B. B. O., Smith, D. J., Koopmans, M., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00384-6 · Cited by 65
Self-citation
Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature
Cantoni, D. M., Wilkie, C., Bentley, E. M., Neto, M. M., Wright, E., Scott, S. D., Ray, S., Castillo‐Olivares, J., Heeney, J. L., Mattiuzzo, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1184362 · Cited by 56
SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models
Mykytyn, A. Z., Breugem, T. I., Geurts, M. H., Beumer, J., Schipper, D., van Acker, R., van den Doel, P. B., van Royen, M. E., Zhang, J., Clevers, H. C., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00851-23 · Cited by 62
Self-citation
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
Rosenke, K., Lewis, M. C., Feldmann, F., Bohrnsen, E., Schwarz, B. H., Okumura, A., Bohler, F., Callison, J. A., Shaia, C., Bosio, C. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.166485 · Cited by 46
When to update COVID-19 vaccine composition
Grant, R., Sacks, J. A., Abraham, P., Chunsuttiwat, S., Cohen, C., Figueroa, J. P., Fleming, T. R., Fine, P., Goldblatt, D., Hasegawa, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02220-y · Cited by 47
Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa
Sun, K., Tempia, S., Kleynhans, J., von Gottberg, A., McMorrow, M. L., Wolter, N., Bhiman, J. N., Moyes, J., Carrim, M., Martinson, N. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35652-0 · Cited by 45
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
Rössler, A., Netzl, A., Knabl, L., Bante, D., Wilks, S. H., Borena, W., von Laer, D., Smith, D. J., & Kimpel, J. (2023) · Nature Communications · doi:10.1038/s41467-023-41049-4 · Cited by 42
Self-citation
Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals
Tan, C. W., Zhu, F., Chia, W. N., Young, B. E., Yeoh, A. Y.-Y., Althaus, T., Yung, C. F., Yap, W. C., Lim, B. L., Chen, M. I.-C., et al. (2023) · hLife · doi:10.1016/j.hlife.2023.07.002 · Cited by 42
Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccinesPreprint
Bowen, J. E., Sprouse, K. R., Walls, A. C., Mazzitelli, I. G., Logue, J. K., Franko, N., Ahmed, K., Ansari, A. S., Cameroni, E., Gori, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.15.484542 · Cited by 38
Classification of five SARS-CoV-2 serotypes based on RBD antigenicities
Hu, S., Wu, C., Wu, X., Ma, X., Shu, C., Chen, Q., Zheng, A., Yang, H., Lü, J., Du, P., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.09.048 · Cited by 40
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35
Antigenic evolution of SARS coronavirus 2
Mykytyn, A. Z., Fouchier, R. A. M., & Haagmans, B. L. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101349 · Cited by 36
Self-citation
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial
Tan, N. H., Geers, D., Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Bogers, S., van Dijk, L. L. A., Gommers, L., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00140-8 · Cited by 37
Self-citation
Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections
Medits, I., Springer, D. N., Graninger, M., Camp, J. V., Höltl, E., Aberle, S. W., Traugott, M. T., Hoepler, W., Deutsch, J., Lammel, O., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946318 · Cited by 37
Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant
Springer, D. N., Perkmann, T., Jani, C. M., Mucher, P., Prüger, K., Marculescu, R., Reuberger, E., Camp, J. V., Graninger, M., Borsodi, C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02129-22 · Cited by 34
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
Muik, A., Lui, B. G., Bacher, M., Wallisch, A.-K., Toker, A., Cadima-Couto, Í., Güler, A., Mampilli, V., Schmitt, G. J., Mottl, J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.ade9888 · Cited by 36
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Cheng, S. M., Mok, C. K. P., Chan, K. C., Ng, S. S., Lam, B. H., Luk, L. L., Ko, F. W., Chen, C., Yiu, K., Li, J. K., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.18.2200178 · Cited by 31
Immune Evasion of SARS-CoV-2 Omicron Subvariants
Ke, H., Chang, M., & Marasco, W. A. (2022) · Vaccines · doi:10.3390/vaccines10091545 · Cited by 29
Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era
Fantini, J., Azzaz, F., Chahinian, H., & Yahi, N. (2023) · Viruses · doi:10.3390/v15020284 · Cited by 30
Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein
Zhang, J., Tang, W., Gao, H., Lavine, C. L., Shi, W. K., Peng, H., Zhu, H., Anand, K., Kosikova, M., Kwon, H. J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01023-6 · Cited by 29
Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong
Leung, D., Duque, J. S. R., Yip, K. M., So, H., Wong, W. H. S., & Lau, Y. (2023) · Communications Medicine · doi:10.1038/s43856-022-00233-1 · Cited by 26
Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology
Wickenhagen, A., Flagg, M., Port, J. R., Yinda, C. K., Goldin, K., Gallogly, S., Schulz, J. E., Lutterman, T. R., Williamson, B. N., Kaiser, F. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55938-3 · Cited by 28
Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD
Li, Q., Zhang, M., Liang, Z., Zhang, L., Wu, X., Yang, C., An, Y., Tong, J., Liu, S., Li, T., et al. (2022) · MedComm · doi:10.1002/mco2.130 · Cited by 26
An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution
Subissi, L., Otieno, J. R., Worp, N., Cohen, H. A., Munnink, B. B. O., Abu-Raddad, L. J., Alm, E., Barakat, A., Barclay, W., Bhiman, J. N., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02949-0 · Cited by 25
Self-citation
Antigenic distance between primary and secondary dengue infections correlates with disease risk
Wang, L., Huang, A. T., Katzelnick, L. C., Lefrancq, N., Escoto, A. C., Duret, L., Chowdhury, N., Jarman, R. G., Conte, M. A., Berry, I. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3259 · Cited by 25
Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study
Hogan, A. B., Wu, S. L., Toor, J., Mesa, D. O., Doohan, P., Watson, O. J., Winskill, P., Charles, G. D., Barnsley, G., Riley, E. M., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004195 · Cited by 27
Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variantsPreprint
Netzl, A., Türeli, S., LeGresley, E. B., Mühlemann, B., Wilks, S., & Smith, D. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.31.474032 · Cited by 25
Self-citation
Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review
Tiecco, G., Storti, S., Arsuffi, S., Degli-Antoni, M., Focà, E., Castelli, F., & Quiros-Roldan, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137315 · Cited by 21
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Pather, S., Muik, A., Rizzi, R., & Mensa, F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2232851 · Cited by 23
Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02663-z · Cited by 23
Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants
Mühlemann, B., Trimpert, J., Walper, F., Schmidt, M. L., Jansen, J., Schroeder, S., Jeworowski, L. M., Beheim-Schwarzbach, J., Bleicker, T., Niemeyer, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310917121 · Cited by 17
Self-citation
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
Zaeck, L. M., Tan, N. H., Rietdijk, W. J. R., Geers, D., Sablerolles, R. S. G., Bogers, S., van Dijk, L. L. A., Gommers, L., van Leeuwen, L. P. M., Rugebregt, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48414-x · Cited by 18
Self-citation
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials
Yang, H. J., Hong, W., Shi, H., He, C., Hong, L., Zhou, Y., Yang, H., Alu, A., Chen, Z., Yang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55087-z · Cited by 18
COVID-19 vaccines versus pediatric hospitalization
Duque, J. S. R., Leung, D., Yip, K. M., Lee, D. H., So, H., Wong, W. H. S., & Lau, Y. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100936 · Cited by 17
SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies
Beukenhorst, A. L., Koch, C. M., Hadjichrysanthou, C., Alter, G., de Wolf, F., Anderson, R. M., & Goudsmit, J. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-00965-x · Cited by 18
Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses
Kassardjian, A., Sun, E., Sookhoo, J. R. V., Muthuraman, K., Boligan, K. F., Kucharska, I., Rujas, E., Jetha, A., Branch, D. R., Babiuk, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112391 · Cited by 17
Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants
Neerukonda, S. N., Wang, R., Vassell, R. A., Baha, H., Lusvarghi, S., Liu, S., Wang, T. T., Weiss, C. D., & Wang, W. (2022) · Journal of Virology · doi:10.1128/jvi.01140-22 · Cited by 16
Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine
Debes, A. K., Xiao, S., Egbert, E. R., Caturegli, P., Gadala, A., Colantuoni, E., Sitaras, I., Pekosz, A. S., & Milstone, A. M. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02046-22 · Cited by 16
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization
Miyamoto, S., Arashiro, T., Ueno, A., Kanno, T., Saito, S., Katano, H., Iida, S., Ainai, A., Ozono, S., Hemmi, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.105969 · Cited by 13
Ultra-sensitive and specific detection of pathogenic nucleic acids using composite-excited hyperfine plasma spectroscopy combs sensitized by Au nanoarrays functionalized with 2D Ta2C-MXene
Yang, W., Liu, R., Yan, J. R., Xie, Y., Wang, C., Jiang, M., Li, P., & Du, L. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115358 · Cited by 16
SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia
Meganck, R. M., Edwards, C. E., Mallory, M. L., Lee, R. E., Dang, H., Bailey, A. B., Wykoff, J. A., Gallant, S. C., Zhu, D. R., Yount, B. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114076 · Cited by 17
Is the time right for systematically serotyping SARS-related coronaviruses?
Tan, C. W., & Wang, L. (2024) · hLife · doi:10.1016/j.hlife.2023.12.007 · Cited by 16
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
Pradenas, E., Marfil, S., Urrea, V., Trigueros, M., Pidkova, T., Pons-Grífols, A., Ortiz, R., Rovirosa, C., Tarrés-Freixas, F., Aguilar‐Gurrieri, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106457 · Cited by 16
Omicron breakthrough infections in vaccinated or previously infected hamsters
Zhou, J., Sukhova, K., McKay, P. F., Kurshan, A., Yau, Y., Lechmere, T., Brown, J. C., Moshe, M., Kugathasan, R., Snell, L. B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308655120 · Cited by 15
Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub
Jung, S.-M., Loo, S. L., Howerton, E., Contamin, L., Smith, C. P., Carcelén, E. C., Yan, K., Bents, S. J., Levander, J. D., Espino, J. U., et al. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004387 · Cited by 15
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Mühlemann, B., Wilks, S. H., Baracco, L., Bekliz, M., Carreño, J. M., Corman, V. M., Davis-Gardner, M. E., Dejnirattisai, W., Diamond, M., Douek, D. C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl1722 · Cited by 19
Self-citation
SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies
Guo, H., Ha, S., Botten, J., Xu, K. Y., Zhang, N., An, Z., Strohl, W. R., Shiver, J. W., & Fu, T. (2024) · Viruses · doi:10.3390/v16050697 · Cited by 19
Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine
Yu, X., Yang, W. J., Li, W., Wan, N., Yan, G., Zhou, Z., Zhu, X. M., Su, W., Li, Y., Xing, C., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.01.005 · Cited by 13
SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion
Ruan, W., Gao, P., Qu, X., Jiang, J., Zhao, Z., Qiao, S., Zhang, H., Yang, T., Li, D., Du, P., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105634 · Cited by 13
Ultra-sensitive specific detection of nucleic acids in pathogenic infections by Ta2C-MXene sensitization-based ultrafine plasmon spectroscopy combs
Yang, W., Yan, J. R., Liu, R., Xie, Y., Wang, C., Kou, Z., Li, P., & Jiang, M. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133785 · Cited by 12
Revolutionizing SARS-CoV-2 omicron variant detection: Towards faster and more reliable methods
Li, D., Sun, C., Zhuang, P., & Mei, X. (2023) · Talanta · doi:10.1016/j.talanta.2023.124937 · Cited by 14
Exploring the Role of Antiviral Nasal Sprays in the Control of Emerging Respiratory Infections in the Community
Hadjichrysanthou, C., Beukenhorst, A. L., Koch, C. M., Alter, G., Goudsmit, J., Anderson, R. M., & de Wolf, F. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00710-z · Cited by 12
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
Geers, D., Sablerolles, R. S. G., van Baarle, D., Kootstra, N. A., Rietdijk, W. J. R., Schmitz, K. S., Gommers, L., Bogers, S., Nieuwkoop, N. J., van Dijk, L. L. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105753 · Cited by 12
Self-citation
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Cheng, S. M. S., Mok, C. K. P., Li, J. K. C., Chan, K. P., Luk, K. S., Lee, B. H. W., Gu, H., Chan, K., Tsang, L. C. H., Yiu, K. Y. S., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02335-9 · Cited by 12
Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
Chao, C.-H., Cheng, D., Huang, S., Chuang, Y., Yeh, T., & Wang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023943 · Cited by 11
Omicron infection increases IgG binding to spike protein of predecessor variants
Mahalingam, G., Periyasami, Y., Arjunan, P., Subaschandrabose, R. K., Mathivanan, T. V., Mathew, R. S., Devi, R., Premkumar, P. S., Muliyil, J., Srivastava, A., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28419 · Cited by 11
Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron
Schröder, S., Richter, A. M., Veith, T., Emanuel, J., Gudermann, L., Friedmann, K., Jeworowski, L. M., Mühlemann, B., Jones, T. C., Müller, M. A., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02154-4 · Cited by 9
Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1
Wang, W., Bhushan, G. L., Paz, S., Stauft, C. B., Selvaraj, P., Goguet, E., Bishop‐Lilly, K. A., Subramanian, R., Vassell, R. A., Lusvarghi, S., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00948-24 · Cited by 10
Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections
Suntronwong, N., Kanokudom, S., Duangchinda, T., Chantima, W., Pakchotanon, P., Klinfueng, S., Puenpa, J., Thatsanathorn, T., Wanlapakorn, N., & Poovorawan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-84138-0 · Cited by 10
Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents
Coombes, N. S., Bewley, K. R., Duff, Y. L., Hurley, M., Smith, L. J., Weldon, T. M., Osman, K. L., Pullan, S. T., Berry, N. J., Hallis, B., et al. (2023) · Viruses · doi:10.3390/v15030633 · Cited by 10
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters
Port, J. R., Yinda, C. K., Riopelle, J. C., Weishampel, Z. A., Saturday, T. A., Avanzato, V. A., Schulz, J. E., Holbrook, M. G., Barbian, K., Perry-Gottschalk, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42346-8 · Cited by 13
A chimeric adenovirus‐vectored vaccine based on Beta spike and Delta RBD confers a broad‐spectrum neutralization against Omicron‐included SARS‐CoV‐2 variants
Hong, W., Hong, L., Peng, D., Huang, Y., He, C., Yang, H. J., Zhou, Y., Liu, J., Pan, X., Que, H., et al. (2024) · MedComm · doi:10.1002/mco2.539 · Cited by 10
Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2
Resch, M. D., Wen, K., Mazboudi, R., Maasz, H. M., Persaud, M., Garvey, K., Gallardo, L., Gottlieb, P., Alimova, A., Khayat, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10121997 · Cited by 10
Neutralizing Immunity Induced Against the Omicron BA.1 and BA.2 Variants in Vaccine Breakthrough Infections
Brazer, N., Morris, M. K., Servellita, V., Anglin, K., Saldhi, P., Garcia-Knight, M., Bethancourt, S., Sotomayor-González, A., Wang, B., Foresythe, A., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac384 · Cited by 9
SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
Aguilar-Bretones, M., den Hartog, Y., van Dijk, L. L. A., Malahe, S. R. K., Dieterich, M., Mora, H. T., Mueller, Y. M., Koopmans, M., Reinders, M. E. J., Baan, C. C., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00886-0 · Cited by 8
Self-citation
Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses
Einhauser, S., Asam, C., Weps, M., Senninger, A., Peterhoff, D., Bauernfeind, S., Asbach, B., Carnell, G., Heeney, J. L., Wytopil, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105438 · Cited by 9
Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice
(2022) · doi:10.3390/v14040800 · Cited by 9
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
Tan, N. H., Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Bogers, S., Geers, D., Zaeck, L. M., Koopmans, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067749 · Cited by 9
Self-citation
Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses
den Hartog, Y., Malahe, S. R. K., Rietdijk, W. J. R., Dieterich, M., Gommers, L., Geers, D., Bogers, S., van Baarle, D., Diavatopoulos, D. A., Messchendorp, A. L., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00664-4 · Cited by 8
Self-citation
Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2
Francis, M. E., Jansen, E. B., Yourkowski, A., Selim, A., Swan, C. L., MacPhee, B. K., Thivierge, B. M., Buchanan, R. M., Lavender, K. J., Darbellay, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41761-1 · Cited by 10
Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
Błaszczuk, A., Michalski, A., Sikora, D., Malm, M., Drop, B., & Polz‐Dacewicz, M. (2022) · Vaccines · doi:10.3390/vaccines10101728 · Cited by 9
Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters
Shiwa-Sudo, N., Sakai, Y., Iwata‐Yoshikawa, N., Watanabe, S., Yamada, S., Kuroda, Y., Yamamoto, T., Shirakura, M., Fujisaki, S., Miyazaki, K., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01366-22 · Cited by 9
Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
Zendt, M., Carrillo, F. A. B., Kelly, S., Saturday, T. A., DeGrange, M., Ginigeme, A., Wu, L., Callier, V., Ortega‐Villa, A. M., Faust, M. T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh3150 · Cited by 11
Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
Rössler, A., Netzl, A., Knabl, L., Wilks, S., Mühlemann, B., Türeli, S., Mykytyn, A. Z., von Laer, D., Haagmans, B. L., Smith, D. J., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00888-y · Cited by 9
Self-citation
Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination
Astakhova, E. A., Morozov, A. A., Byazrova, M. G., Sukhova, M. M., Mikhailov, A. A., Minnegalieva, A. R., Gorchakov, A. A., & Filatov, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310493 · Cited by 9
A Multivariant Surrogate Neutralization Assay Identifies Variant-Specific Neutralizing Antibody Profiles in Primary SARS-CoV-2 Omicron Infection
Springer, D. N., Traugott, M. T., Reuberger, E., Kothbauer, K. B., Borsodi, C., Naegeli, M., Oelschlägel, T., Kelani, H., Lammel, O., Deutsch, J., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13132278 · Cited by 7
A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories
Brangel, P., Türeli, S., Mühlemann, B., Liechti, N., Zysset, D., Engler, O. B., Hunger‐Glaser, I., Ghiga, I., Mattiuzzo, G., Eckerle, I., et al. (2024) · Viruses · doi:10.3390/v16121936 · Cited by 8
Self-citation
Rapid and Sensitive Screening of Trace Infectious Disease Nucleic Acids Using a High-Density Surface Modified AuNPs@Ta 2 C-MXene/Au/TFBG Sensor
Yan, J. R., Yang, W., Liu, R., Xie, Y., Jiang, S., Li, P., Wang, C., Sui, Q., Liu, T., & Jiang, M. (2023) · Journal of Lightwave Technology · doi:10.1109/jlt.2023.3338849 · Cited by 7
Safety and immunogenicity of an adjuvanted recombinant spike protein‐based severe acute respiratory syndrome coronavirus 2 ( SARS‐CoV ‐2) vaccine, SpikeVet ™, in selected Carnivora, Primates and Artiodactyla in Australian zoos
McLelland, D. J., Lynch, M., Vogelnest, L., Eden, P. A., Wallace, A. M., Weller, J., Young, S., Vaughan‐Higgins, R., Antipov, A., Honda‐Okubo, Y., et al. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13429 · Cited by 7
A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants
Chen, J., Huang, Z., Xiao, J., Du, S., Bu, Q., Guo, H., Ye, J., Chen, S., Gao, J., Li, Z., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100856 · Cited by 7
Managing sources of error during pandemics
Cauchemez, S., Bosetti, P., & Cowling, B. J. (2023) · Science · doi:10.1126/science.add3173 · Cited by 7
Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters
Diego, J. G.-B., Singh, G., Jangra, S., Handrejk, K., Laporte, M., Chang, L. A., Zahed, S. S. E., Pache, L., Chang, M. W., Warang, P., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011805 · Cited by 8
Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost
Nair, M. S., Ribeiro, R. M., Wang, M., Bowen, A. D., Liu, L., Guo, Y., Chang, J. Y., Wang, P., Sheng, Z., Sobieszczyk, M. E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106345 · Cited by 5
Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamstersPreprint
Port, J. R., Yinda, C. K., Riopelle, J. C., Weishampel, Z. A., Saturday, T. A., Avanzato, V. A., Schulz, J. E., Holbrook, M. G., Barbian, K., Perry-Gottschalk, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.29.502072 · Cited by 6
Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster seraPreprint
Wang, W., Bhushan, G. L., Paz, S., Stauft, C. B., Selvaraj, P., Goguet, E., Bishop‐Lilly, K. A., Subramanian, R., Vassell, R. A., Lusvarghi, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.05.588359 · Cited by 6
Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies
Marvelde, M. R. T., Mykytyn, A. Z., Kroeze, E. J. B. V., Bouffier, A., van Eck—Schipper, D., van den Doel, P., Handrejk, K., Koel, B. F., Rissmann, M., & Haagmans, B. L. (2026) · npj Vaccines · doi:10.1038/s41541-025-01348-x · Cited by 6
Self-citation
Mapping antibody footprints using binding profiles
Azulay, A., Cohen-Lavi, L., Friedman, L. M., McGargill, M. A., & Hertz, T. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100566 · Cited by 5
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Oyebanji, O. A., Sundheimer, N., Ragavapuram, V., Wilson, B. M., Abul, Y., Gravenstein, S., Bosch, J., King, C. L., & Canaday, D. H. (2024) · GeroScience · doi:10.1007/s11357-024-01215-y · Cited by 5
Resistance to SARS-CoV-2 infection in camelid nasal organoids is associated with lack of ACE2 expression
Breugem, T. I., Riesebosch, S., Schipper, D., Mykytyn, A. Z., van den Doel, P., Segalés, J., Lamers, M. M., & Haagmans, B. L. (2024) · npj Viruses · doi:10.1038/s44298-024-00054-0 · Cited by 6
Self-citation
Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination
Jia, T., Wang, F., Chen, Y., Liao, G., Xu, Q., Chen, J., Wu, J., Li, N., Wang, L., Yuan, L., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106362 · Cited by 7
Population-based screening in a municipality after a primary school outbreak of the SARS-CoV-2 Alpha variant, the Netherlands, December 2020–February 2021
van Beek, J., Teesing, G. R., Munnink, B. B. O., Meima, A., Vriend, H. J., Elzakkers, J., de Graaf, M., Langeveld, J., Medema, G. J., Molenkamp, R., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276696 · Cited by 5
Self-citation
Exploring geometry of genome space via Grassmann manifolds
Li, X., Zhou, T., Feng, X., Yau, S., & Yau, S. S. ‐. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100677 · Cited by 6

Authors: Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., van Royen, M. E., Molenkamp, R., Oude Munnink, B. B., de Vries, R. D., GeurtsvanKessel, C., Smith, D. J., Koopmans, M. P. G., Rockx, B., Lamers, M. M., Fouchier, R. A. M., & Haagmans, B. L.
Affiliations: Erasmus MC (NL)
Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands.
Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands.
University of Cambridge (GB)
Corresponding author: Rissmann, Melanie
Kok, Adinda
Rosu, Miruna E.
Haagmans, Bart L.
ORCID: Mykytyn, Anna Z.
Rissmann, Melanie
Kok, Adinda
Rosu, Miruna E.
Schipper, Debby
Breugem, Tim I.
van den Doel, Petra B.
Chandler, Felicity
de Wit, Maurice
van Royen, Martin E.
Molenkamp, Richard
Oude Munnink, Bas B.
de Vries, Rory D.
GeurtsvanKessel, Corine
Smith, Derek J.
Koopmans, Marion P. G.
Rockx, Barry
Lamers, Mart M.
Fouchier, Ron A. M.
Haagmans, Bart L.
Venue: Science Immunology
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2022-09-30
Volume: 7
Issue: 75
Pages: eabq4450-eabq4450
ISSN: 2470-9468 (ISSN-L)
DOI: 10.1126/sciimmunol.abq4450
PMC: PMC9273038
OpenAlex: W4283330057
Cited by: 153
References: 35
Citations by year: 2026: 11 · 2025: 16 · 2024: 43 · 2023: 49 · 2022: 34
FWCI: 17.33
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: cc-by
Locations: Science Immunology (publishedVersion)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Apollo (University of Cambridge) (submittedVersion, cc-by)
Apollo (cc-by)
Funders: Health~Holland (EMCLHS20017, LSHM19136)
European Commission (874735, 101003589, 75N93021C00014)
ZonMw (10150062010008)
Erasmus Medisch Centrum
National Institutes of Health (75N93021C00014, 874735, 101003589)
National Institute of Allergy and Infectious Diseases (#75N93021C00014, 101003589, 874735)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, Omicron BA.1, Omicron BA.2, antigenic cartography, antigenic drift, spike protein mutations, neutralizing antibodies, vaccine escape, spike protein, Calu-3 cells, Vero E6 cells, SARS-CoV-2 variants
MeSH terms: COVID-19, SARS-CoV-2, Animals, Cell Line, Cricetinae, Humans, Immune Sera

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks